JP2016199602A5 - - Google Patents

Download PDF

Info

Publication number
JP2016199602A5
JP2016199602A5 JP2016174293A JP2016174293A JP2016199602A5 JP 2016199602 A5 JP2016199602 A5 JP 2016199602A5 JP 2016174293 A JP2016174293 A JP 2016174293A JP 2016174293 A JP2016174293 A JP 2016174293A JP 2016199602 A5 JP2016199602 A5 JP 2016199602A5
Authority
JP
Japan
Prior art keywords
dosage form
pharmaceutical dosage
tofacitinib
cmax
cmin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016174293A
Other languages
English (en)
Japanese (ja)
Other versions
JP6314188B2 (ja
JP2016199602A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016199602A publication Critical patent/JP2016199602A/ja
Publication of JP2016199602A5 publication Critical patent/JP2016199602A5/ja
Application granted granted Critical
Publication of JP6314188B2 publication Critical patent/JP6314188B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016174293A 2013-03-16 2016-09-07 トファシチニブの経口持続放出剤形 Active JP6314188B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361802479P 2013-03-16 2013-03-16
US61/802,479 2013-03-16
US201361864059P 2013-08-09 2013-08-09
US61/864,059 2013-08-09
US201461934428P 2014-01-31 2014-01-31
US61/934,428 2014-01-31

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014045951A Division JP6041823B2 (ja) 2013-03-16 2014-03-10 トファシチニブの経口持続放出剤形

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018058176A Division JP2018100300A (ja) 2013-03-16 2018-03-26 トファシチニブの経口持続放出剤形

Publications (3)

Publication Number Publication Date
JP2016199602A JP2016199602A (ja) 2016-12-01
JP2016199602A5 true JP2016199602A5 (OSRAM) 2017-04-13
JP6314188B2 JP6314188B2 (ja) 2018-04-18

Family

ID=50819757

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014045951A Active JP6041823B2 (ja) 2013-03-16 2014-03-10 トファシチニブの経口持続放出剤形
JP2016174293A Active JP6314188B2 (ja) 2013-03-16 2016-09-07 トファシチニブの経口持続放出剤形
JP2018058176A Pending JP2018100300A (ja) 2013-03-16 2018-03-26 トファシチニブの経口持続放出剤形

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2014045951A Active JP6041823B2 (ja) 2013-03-16 2014-03-10 トファシチニブの経口持続放出剤形

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018058176A Pending JP2018100300A (ja) 2013-03-16 2018-03-26 トファシチニブの経口持続放出剤形

Country Status (22)

Country Link
US (4) US9937181B2 (OSRAM)
EP (3) EP4249055A3 (OSRAM)
JP (3) JP6041823B2 (OSRAM)
KR (5) KR20220151016A (OSRAM)
CN (2) CN111419817A (OSRAM)
AU (2) AU2014233850B2 (OSRAM)
BR (1) BR112015020453B1 (OSRAM)
CA (2) CA3037328C (OSRAM)
CY (1) CY1124007T1 (OSRAM)
DK (1) DK2968155T3 (OSRAM)
ES (1) ES2865134T3 (OSRAM)
HU (1) HUE053911T2 (OSRAM)
IL (3) IL241400B (OSRAM)
MX (1) MX2021000550A (OSRAM)
NZ (2) NZ751227A (OSRAM)
PL (1) PL2968155T3 (OSRAM)
PT (1) PT2968155T (OSRAM)
SG (2) SG10201810985XA (OSRAM)
SI (1) SI2968155T1 (OSRAM)
TW (1) TWI619516B (OSRAM)
WO (1) WO2014147526A1 (OSRAM)
ZA (2) ZA201505468B (OSRAM)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2759924B2 (ja) 1995-08-11 1998-05-28 株式会社ゼクセル 燃料噴射装置の噴射時期検出装置
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
GB201402070D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
EP3157526A1 (en) * 2014-06-23 2017-04-26 Sun Pharmaceutical Industries Ltd Oral pharmaceutical composition of tofacitinib
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
CN104622827A (zh) * 2015-03-05 2015-05-20 重庆华邦制药有限公司 托法替布片剂及其制备方法
AU2016272089B2 (en) * 2015-06-03 2021-02-18 Triastek, Inc. Dosage forms and use thereof
CA2987867C (en) * 2015-06-09 2023-06-27 Capsugel Belgium Nv Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
US20180214383A1 (en) * 2015-07-16 2018-08-02 National University Of Singapore Printing drug tablets with fully customizable release profiles for personalized medicine
EP3328360A4 (en) * 2015-07-27 2019-01-02 Unichem Laboratories Limited Tofacitinib orally disintegrating tablets
WO2017029587A1 (en) * 2015-08-19 2017-02-23 Sun Pharmaceutical Industries Limited Sustained release oral pharmaceutical compositions of tofacitinib
US20180311247A1 (en) * 2015-10-02 2018-11-01 Gilead Sciences, Inc. Combination therapies for treating cancers
RU2018117889A (ru) 2015-10-16 2019-11-20 Эббви Инк. СПОСОБЫ ПОЛУЧЕНИЯ (3S,4R)-3-ЭТИЛ-4-(3H-ИМИДАЗО[1,2-a]ПИРРОЛО[2,3-e]-ПИРАЗИН-8-ИЛ)-N-(2,2,2-ТРИФТОРЭТИЛ)ПИРРОЛИДИН-1-КАРБОКСАМИДА И ЕГО ТВЕРДОФАЗНЫХ ФОРМ
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN109069475B (zh) 2016-04-22 2022-01-28 受体控股公司 快速作用植物类医药化合物和营养补剂
CN108066319B (zh) * 2016-11-10 2022-01-14 江苏先声药业有限公司 一种枸橼酸托法替布肠溶缓释微丸及其制备方法
CN106420648A (zh) * 2016-11-22 2017-02-22 山东淄博新达制药有限公司 枸橼酸托法替布片剂及其制备方法
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
KR20180066296A (ko) * 2016-12-07 2018-06-19 서울대학교산학협력단 토파시티닙을 포함하는 고염증 증상의 예방 또는 치료용 약학적 조성물 및 토파시티닙을 포함하는 고염증 증상의 예방 또는 개선용 건강기능식품 조성물
JP7191385B2 (ja) 2017-01-26 2022-12-19 トリアステック インコーポレイテッド 特定の胃腸部位での制御放出の剤形
US10472366B2 (en) * 2017-03-08 2019-11-12 Theravance Biopharma R&D Ip, Llc Glucuronide prodrugs of tofacitinib
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
US20190046527A1 (en) 2017-03-09 2019-02-14 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
US10759865B2 (en) 2017-08-22 2020-09-01 Eyal Levit Treatment of diabetes mellitus
KR102078805B1 (ko) * 2017-11-30 2020-02-19 보령제약 주식회사 토파시티닙을 포함하는 약제학적 조성물
WO2019224058A1 (en) 2018-05-24 2019-11-28 Synthon B.V. Controlled release tofacitinib compositions
US20190381046A1 (en) * 2018-06-14 2019-12-19 Andrew HANNA Tofacitinib and baclofen compositions and applications
CN108992454B (zh) * 2018-06-20 2020-06-02 合肥医工医药股份有限公司 一种治疗皮肤炎症性疾病的复方药物组合物
CN110946834B (zh) * 2018-09-27 2023-03-31 四川科伦药物研究院有限公司 枸橼酸托法替布片及其制备工艺
CN111150711B (zh) * 2018-11-07 2023-04-07 上海博志研新药物技术有限公司 托法替布控释片、制备方法及其应用
UY38480A (es) 2018-11-19 2020-06-30 Receptor Holdings Inc Aminoácidos grasos n-acilados para reducir la variabilidad de absorción en composiciones a base de cannabinoides
CN111358795A (zh) * 2018-12-26 2020-07-03 浙江万晟药业有限公司 一种枸橼酸托法替布制剂及其制备方法
KR20200082006A (ko) * 2018-12-28 2020-07-08 주식회사 대웅제약 토파시티닙 또는 그의 약제학적으로 허용되는 염을 함유한 서방성 제제 및 그의 제조방법
EP3946318A4 (en) * 2019-03-27 2022-12-28 Unichem Laboratories Ltd TOFACITINIB EXTENDED-RELEASE COMPOSITION
WO2021038014A1 (en) 2019-08-29 2021-03-04 Synthon B.V. Controlled release tofacitinib compositions
CN114727950A (zh) * 2019-11-14 2022-07-08 辉瑞大药厂 1-(((2s,3s,4s)-3-乙基-4-氟-5-氧代吡咯烷-2-基)甲氧基)-7-甲氧基异喹啉-6-羧酰胺组合及口服剂型
CN110787145B (zh) * 2019-12-17 2022-03-29 南京康川济医药科技有限公司 一种枸橼酸托法替布缓释片及其制备方法
CN113018273B (zh) * 2019-12-25 2024-08-09 上海宣泰医药科技股份有限公司 一种固体制剂及其制备方法和用途
CN113384544A (zh) * 2020-02-26 2021-09-14 上海博志研新药物技术有限公司 托法替尼缓释剂型、其制备方法及应用
JP7442347B2 (ja) * 2020-03-06 2024-03-04 東京エレクトロン株式会社 基板処理装置及び基板処理方法
US11766438B2 (en) 2020-04-24 2023-09-26 Slayback Pharma Llc Pharmaceutical compositions of tofacitinib for oral administration
US20230172934A1 (en) * 2020-05-18 2023-06-08 Zim Laboratories Limited Novel extended release composition of tofacitinib, its derivatives and salts
CN113712932A (zh) * 2020-05-25 2021-11-30 南京帝昌医药科技有限公司 一种枸橼酸托法替布渗透泵片及其制备方法
US20230270666A1 (en) 2020-07-28 2023-08-31 Fang Zhou Novel gastroretentive extended release dosage form
CN111728953B (zh) * 2020-07-29 2023-08-08 中国科学院上海药物研究所 一种托法替布或其盐的缓释制剂及其制备方法
CN114099499A (zh) * 2020-08-26 2022-03-01 上海博志研新药物技术有限公司 依达拉奉口服持续释放组合物、制备方法及应用
CN112755000A (zh) * 2021-01-21 2021-05-07 石药集团欧意药业有限公司 一种枸橼酸托法替布缓释片
CN113069434A (zh) * 2021-03-11 2021-07-06 绍兴文理学院元培学院 一种枸橼酸托法替布控释胶囊及其制备方法
EP4347028A1 (en) 2021-06-04 2024-04-10 Synthon B.V. Prolonged release tofacitinib compositions
KR102589344B1 (ko) * 2021-11-16 2023-10-16 오즈온바이오 주식회사 산 민감성 성분을 포함하는 삼투성 제제 조성물
US20230240998A1 (en) * 2021-12-22 2023-08-03 Hikma Pharmaceuticals Usa Inc. Tofacitinib extended release formulations
AU2023329168A1 (en) 2022-08-26 2025-03-20 Synthon B.V. Prolonged release tofacitinib compositions without functional coating
CN116115580A (zh) * 2023-02-17 2023-05-16 北大医药股份有限公司 一种枸橼酸托法替布缓释片及其制备方法
AU2024247059A1 (en) * 2023-03-29 2025-10-30 Merck Sharp & Dohme (Uk) Limited Controlled release pde10a formulations
KR102793673B1 (ko) * 2025-02-04 2025-04-11 삼익제약주식회사 바리시티닙을 포함하는 장기지속형 미립구의 제조 방법 및 이의 제조 방법으로 제조된 바리시티닙을 포함하는 장기지속형 미립구

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2322793A (en) 1939-08-21 1943-06-29 Robert S Drummond Gear finishing tool
US3247066A (en) 1962-09-12 1966-04-19 Parke Davis & Co Controlled release dosage form containing water-swellable beadlet
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3952741A (en) 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
US4519801A (en) 1982-07-12 1985-05-28 Alza Corporation Osmotic device with wall comprising cellulose ether and permeability enhancer
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IL91398A (en) 1988-08-30 1994-05-30 Pfizer Pharmaceutical delivery device comprising active substance surrounded by asymmetric membrane
US5358502A (en) * 1993-02-25 1994-10-25 Pfizer Inc PH-triggered osmotic bursting delivery devices
DE69425453T2 (de) * 1993-04-23 2001-04-12 Novartis Ag, Basel Wirkstoffabgabevorrichtung mit gesteuerter Freigabe
EP0758244B2 (en) 1994-05-06 2008-02-13 Pfizer Inc. Controlled-release dosage forms of azithromycin
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
US5736159A (en) 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
US5837379A (en) 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
JP2000514101A (ja) 1997-07-01 2000-10-24 ファイザー・インク セルトラリン塩及びセルトラリンの持続性剤形
FR2766708B1 (fr) 1997-07-30 2000-05-05 Galenix Dev Composition contenant de l'hydroxypropylcellulose, de l'hydroxypropylmethylcellulose et/ou de l'ethylcellullose a titre d'agents desintegrants, et procede d'obtention
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
CN1195755C (zh) 1999-12-10 2005-04-06 辉瑞产品公司 吡咯并[2,3－d]嘧啶化合物
IN190699B (OSRAM) 2001-02-02 2003-08-16 Sun Pharmaceutical Ind Ltd
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
CN100534531C (zh) * 2001-11-13 2009-09-02 山之内制药技术股份有限公司 可溶的药物缓释系统
GB0127423D0 (en) 2001-11-15 2002-01-09 Glaxo Group Ltd Process
GT200200234A (es) 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
US20030175346A1 (en) 2002-02-01 2003-09-18 Anne Billotte Osmotic delivery system
AR046811A1 (es) 2003-09-02 2005-12-28 Imran Ahmed Formas de dosificacion oral de ziprasidona de liberacion sostenida
US7825106B2 (en) 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
BRPI0416534A (pt) 2003-12-04 2007-01-09 Pfizer Prod Inc composições multiparticuladas com estabilidade melhorada
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
KR20080064209A (ko) 2003-12-04 2008-07-08 화이자 프로덕츠 인코포레이티드 바람직하게는 폴록사머와 글리세라이드를 함유하는다미립자 아지트로마이신 조성물의 제조를 위해 압출기를사용하는 분무응결 방법
JP2008524317A (ja) 2004-12-21 2008-07-10 ファイザー・プロダクツ・インク 腸溶コーティングされたアジスロマイシン多粒子
WO2006081569A2 (en) * 2005-01-27 2006-08-03 Alza Corporation Oral osmotic dosage form having a high flux membrane
WO2007019393A2 (en) * 2005-08-04 2007-02-15 Alza Corporation Osmotic dosage forms comprising semipermeable membranes with polymer blends providing improved properties
WO2007057762A2 (en) * 2005-11-16 2007-05-24 Pfizer Limited Osmotic bi-layer tablet
RU2403016C2 (ru) * 2006-04-24 2010-11-10 Пфайзер Продактс Инк. Асимметричные мембраны для устройств доставки лекарственного препарата
EP2043598A4 (en) * 2006-06-30 2012-08-01 Univ Arkansas PERFORATED TABLET WITH EXTENDED RELEASE
CA2759026C (en) 2009-04-20 2019-01-15 Auspex Pharmaceuticals, Inc. Piperidine inhibitors of janus kinase 3
WO2011039686A1 (en) * 2009-09-30 2011-04-07 Pfizer Inc. Latrepirdine oral sustained release dosage forms
US8519970B2 (en) 2010-07-16 2013-08-27 Perceptive Pixel Inc. Capacitive touch sensor having correlation with a receiver
EP2481397A1 (en) 2011-01-27 2012-08-01 Ratiopharm GmbH Pharmaceutical compositions comprising tasocitinib
EP2481411A1 (en) * 2011-01-27 2012-08-01 Ratiopharm GmbH Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
WO2014174073A1 (en) 2013-04-26 2014-10-30 Sandoz Ag Sustained release formulations of tofacitinib

Similar Documents

Publication Publication Date Title
JP2016199602A5 (OSRAM)
JP2014181234A5 (OSRAM)
JP2016006108A5 (OSRAM)
AU654277B2 (en) Controlled release drug formulation
HRP20180965T1 (hr) Formulacija lijeka s produženim otpuštanjem
NO335070B1 (no) Tidsstyrt vedvarende frigivelses multipartikulære doseringsformer av propranolol
JP2009537611A5 (ja) リポ酸のペレット
JP7041333B2 (ja) 放出調節コーティングカプセル
JP2007119479A5 (OSRAM)
JP2005526043A5 (OSRAM)
RU2012131158A (ru) Фармацевтическая композиция с контролируемым высвобождением лекарственного средства
JP2019506401A5 (OSRAM)
WO2013046453A1 (ja) 易服用性固形製剤
JP2017515880A (ja) 放出調節コーティングカプセル
TWI508755B (zh) 供三甲氧苄嗪（ｔｒｉｍｅｔａｚｉｄｉｎｅ）延長釋放之醫藥組合物
CN103948556A (zh) 一种新型控释片
CN105769773B (zh) 洛索洛芬钠缓释微丸
CN102091053A (zh) 一种颗粒组合控释片
JP2010521437A5 (OSRAM)
JP2016512493A5 (OSRAM)
JP2015533174A (ja) ピロカルピンの医薬製剤
JP2010506855A5 (OSRAM)
JP2009521526A5 (OSRAM)
JP6626492B2 (ja) コハク酸メトプロロールのカプセル剤形
JP4711499B2 (ja) 多細孔性食物防護